Plasma NGAL in APN Patients

Kafrelsheikh University

Status: Completed

Conditions: Pyelonephritis

Treatments: Diagnostic Test: Plasma NGAL test

Study type: Observational

Funder types: Other

Identifiers

NCT06802796

KFSIRB200-143

Details and patient eligibility

About

In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs. NGAL is a 25 kDa protein that belongs to the lipocalin. It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis

Enrollment: 120 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• above 20 years Suspected have pyelonphirtis

Exclusion criteria

• age below 20

Trial design

120 participants in 2 patient groups

Group A :patient with pyelonephritis

Description:

patient with pyelonephritis

Treatment:

Diagnostic Test: Plasma NGAL test

Group B :patient without pyelonephritis

Description:

patient without pyelonephritis

Treatment:

Diagnostic Test: Plasma NGAL test